One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Gender disparities in publishing: from words to actions
doi : 10.1016/S2213-8587(21)00214-X
Volume 9, Issue 9, September 2021, Page 545
Type 1 diabetes: one size does not fit all
doi : 10.1016/S2213-8587(21)00216-3
Volume 9, Issue 9, September 2021, Page 545
GLP-1 receptor agonists: which added value when increasing the dose?
André JScheenab
doi : 10.1016/S2213-8587(21)00205-9
Volume 9, Issue 9, September 2021, Pages 546-548
Cardiovascular disease in type 1 diabetes: a continuing challenge
Trevor JOrcharda
doi : 10.1016/S2213-8587(21)00190-X
Volume 9, Issue 9, September 2021, Pages 548-549
Dapagliflozin in patients with COVID-19: truth or dare
XavierRosselloabcdFranciscaCaimarie
doi : 10.1016/S2213-8587(21)00206-0
Volume 9, Issue 9, September 2021, Pages 550-551
Targeting visceral adiposity with pharmacotherapy
Kishore MGaddeaSteven BHeymsfielda
doi : 10.1016/S2213-8587(21)00204-7
Volume 9, Issue 9, September 2021, Pages 551-552
Defining a cure for type 1 diabetes: a call to action
Bart ORoepabEnriqueMonteroaRenévan TienhovenaMark AAtkinsoncDesmond ASchatzdChantalMathieue
doi : 10.1016/S2213-8587(21)00181-9
Volume 9, Issue 9, September 2021, Pages 553-555
Scientific medical conferences can be easily modified to improve female inclusion: a prospective study
VictoriaSalemacdJordanMcDonaghaElizabethAvisaPei ChiaEngaSueSmithbKevin GMurphya
doi : 10.1016/S2213-8587(21)00177-7
Volume 9, Issue 9, September 2021, Pages 556-559
Ashley Grossman: finding a calling in neuroendocrinology
RayCavanaugh
doi : 10.1016/S2213-8587(21)00171-6
Volume 9, Issue 9, September 2021, Page 560
Obesity in Qatar: current and future strategies
ShahradTaheriabcMohammedAl-Thanid
doi : 10.1016/S2213-8587(21)00209-6
Volume 9, Issue 9, September 2021, Pages 561-562
Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
Juan PFríasMDaPernilleAuerbachMDbHarpreet SBajajMDcYasushiFukushimaMDdIldikoLingvayMDefStanislavaMacuraMDbAnette LSøndergaardPhDbTsvetalina ITankovaMDgNikolaosTentolourisMDhJohn BBuseMDi
doi : 10.1016/S2213-8587(21)00174-1
Volume 9, Issue 9, September 2021, Pages 563-574
Long-term population-based trends in the incidence of cardiovascular disease in individuals with type 1 diabetes from Finland: a retrospective, nationwide, cohort study
ValmaHarjutsaloPhDabcdDrazenkaPongrac BarlovicDMScabcefProfPer-HenrikGroopDMScabcg
doi : 10.1016/S2213-8587(21)00172-8
Volume 9, Issue 9, September 2021, Pages 575-585
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial
ProfMikhail NKosiborodMDabcRussellEsterlinePhDdProfRemo H MFurtadoMDefJanOscarssonMDgSamvel BGasparyanPhDgProfGary GKochPhDhProfFelipeMartinezMDiOmarMukhtarMRCPjProfSubodhVermaMDklVijayChopraMDmJoanBuenconsejoPhDdAnna MariaLangkildePhDgPhilipAmberyFRCPgFengmingTangMSaKenseyGoschMSaSheryl LWindsorBSaEmily EAkinMBAnRonaldo V PSoaresPharmDeDiogo D FMoiaPharmDeMatthewAboudaraMDoConrado RobertoHoffmann FilhoMDpAudes D MFeitosaMDqAlbertoFonsecaMDrVishnuGarlaMDstRobert AGordonMDuAliJavaheriMDvCristiano PJaegerMDwPaulo ELeaesMDxMichaelNassifMDaMichaelPursleyMDyFabio SerraSilveiraMDzProfWeimar Kunz SebbaBarrosoMDaaabJosé RobertoLazcano SotoMDacLiliaNigro MaiaMDadProfOtavioBerwangerMDe
doi : 10.1016/S2213-8587(21)00180-7
Volume 9, Issue 9, September 2021, Pages 586-594
Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial
Ian JNeelandMDaProfSteven PMarsoMDbColby RAyersMScBienkaLewisMPHcRobertOslicaBAcWynonaFrancisBSdSusanRodderRDcAmbarishPandeyMDcParag HJoshiMHSc
doi : 10.1016/S2213-8587(21)00179-0
Volume 9, Issue 9, September 2021, Pages 595-605
Nutritional intake and bone health
ProfRenéRizzoliMDaEmmanuelBiverMDaTara CBrennan-SperanzaPhDb
doi : 10.1016/S2213-8587(21)00119-4
Volume 9, Issue 9, September 2021, Pages 606-621
Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group
Jenneke Evan AtteveldMDaRenée LMulderPhDaProfMarry Mvan den Heuvel-EibrinkMDaProfMelissa MHudsonMDbdProfLeontien C MKremerPhDaProfRoderickSkinnerPhDeProfW HamishWallaceMDfProfLouis SConstineMDgClaire EHighamPhDhProfSue CKasteDObcRiittaNiinimäkiMDiSogolMostoufi-MoabMDjProfNathalieAlosMDkDaniloFintiniMDlProfKimberly JTempletonMDmProfLeanne MWardMDnEvaFreyMDoRobertoFranceschiMDpVesnaPavasovicMDqSeth EKarolMDbNadia LAminPhDrLynda MVroomanMDsArjaHarila-SaariMDtCharlotteDemoor-GoldschmidtMDuvaiRobert DMurrayMDwEditBardiMDxyMaarten HLequinMDazProfMaria FeliciaFaienzaMDaaOlgaZaikovaMDabClaireBergerPhDacadStefanoMoraMDaeProfKirsten KNessPhDdSebastian J C M MNeggersMDafSaskia M FPluijmPhDa*ProfJill HSimmonsMDag*ProfNatasciaDi IorgiMDah*
doi : 10.1016/S2213-8587(21)00173-X
Volume 9, Issue 9, September 2021, Pages 622-637
Black oesophagus in an adolescent with type 2 diabetes
PaoloQuitadamoMDabFloraCarusoMDbCristinaBucciPhDbCasimiroDel MonacoMDcAlessandraVerdeMDdAngelaZanfardinoMDeCaterinaStrisciuglioPhDeAlessiaPiscopoMDeProfDarioIafuscoMDeAugustoMastrominicoMDaMarianoCaldoreMDb
doi : 10.1016/S2213-8587(21)00187-X
Volume 9, Issue 9, September 2021, Page 638
